IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.711
NA - Nord America 13.354
AS - Asia 6.797
SA - Sud America 1.140
Continente sconosciuto - Info sul continente non disponibili 856
AF - Africa 424
OC - Oceania 30
AN - Antartide 1
Totale 36.313
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.986
IT - Italia 4.313
RU - Federazione Russa 2.977
SG - Singapore 2.249
CN - Cina 1.523
GB - Regno Unito 1.520
IE - Irlanda 1.505
BR - Brasile 929
VN - Vietnam 885
DE - Germania 772
HK - Hong Kong 712
SE - Svezia 657
FR - Francia 585
FI - Finlandia 470
IN - India 329
ZA - Sudafrica 215
KR - Corea 214
BD - Bangladesh 213
NL - Olanda 202
CA - Canada 198
ES - Italia 147
UA - Ucraina 137
JP - Giappone 109
PL - Polonia 90
IQ - Iraq 87
MX - Messico 85
TR - Turchia 72
CZ - Repubblica Ceca 71
CI - Costa d'Avorio 57
AR - Argentina 56
AT - Austria 52
PK - Pakistan 43
ID - Indonesia 40
NG - Nigeria 40
IR - Iran 38
EC - Ecuador 35
CH - Svizzera 33
SA - Arabia Saudita 32
VE - Venezuela 32
BE - Belgio 30
KE - Kenya 30
PH - Filippine 30
MA - Marocco 29
UZ - Uzbekistan 29
AE - Emirati Arabi Uniti 25
AU - Australia 25
CO - Colombia 25
CL - Cile 20
MY - Malesia 19
LT - Lituania 18
PE - Perù 18
AZ - Azerbaigian 15
EG - Egitto 15
JM - Giamaica 15
PT - Portogallo 15
JO - Giordania 14
BG - Bulgaria 13
HU - Ungheria 13
IL - Israele 13
KZ - Kazakistan 13
RO - Romania 13
TT - Trinidad e Tobago 12
EE - Estonia 11
NP - Nepal 11
PY - Paraguay 11
DZ - Algeria 10
LB - Libano 10
LV - Lettonia 10
PA - Panama 10
TN - Tunisia 10
CR - Costa Rica 8
DK - Danimarca 8
GE - Georgia 8
GR - Grecia 8
OM - Oman 8
BO - Bolivia 7
KG - Kirghizistan 7
BY - Bielorussia 6
CY - Cipro 6
EU - Europa 6
GT - Guatemala 6
LK - Sri Lanka 6
TW - Taiwan 6
AL - Albania 5
HR - Croazia 5
MK - Macedonia 5
NO - Norvegia 5
PR - Porto Rico 5
QA - Qatar 5
SN - Senegal 5
SV - El Salvador 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
LA - Repubblica Popolare Democratica del Laos 4
NI - Nicaragua 4
PS - Palestinian Territory 4
AM - Armenia 3
BH - Bahrain 3
Totale 35.407
Salva come PNG Salva come JPEG
Città #
Dallas 2.253
Dublin 1.477
Singapore 1.381
Southend 1.187
San Jose 1.103
Ashburn 1.071
Moscow 912
Santa Clara 856
Milan 824
Hong Kong 654
Chandler 624
Fairfield 618
Council Bluffs 539
Siena 478
Beijing 424
Los Angeles 386
Munich 348
Lastra a Signa 340
Helsinki 328
Hefei 323
New York 300
Rome 299
Ho Chi Minh City 255
Houston 253
Florence 252
Seattle 233
Woodbridge 232
Wilmington 227
Hanoi 210
Seoul 205
Johannesburg 199
Lauterbourg 197
Princeton 187
Cambridge 180
The Dalles 135
Ann Arbor 126
Chicago 105
São Paulo 100
Columbus 93
Shanghai 89
Tokyo 83
Buffalo 79
Jacksonville 78
Warsaw 75
Orem 74
Bengaluru 73
Frankfurt am Main 68
Redondo Beach 68
London 67
Boardman 66
Nuremberg 65
Dong Ket 64
Fremont 64
Turku 64
San Mateo 60
Lappeenranta 59
Málaga 59
Abidjan 57
Figino 55
San Diego 54
Düsseldorf 52
Chennai 51
Turin 51
Da Nang 49
Portsmouth 49
Dearborn 48
Montreal 48
Phoenix 48
Toronto 47
Brooklyn 46
Naples 46
Boston 44
Washington 42
Atlanta 40
Brno 40
Denver 37
Haiphong 37
Stockholm 37
Amsterdam 35
Brescia 35
Baghdad 33
Abuja 32
Bologna 32
Manchester 32
Poplar 32
Mumbai 28
San Francisco 28
Newark 26
Rio de Janeiro 26
Tashkent 26
Vienna 26
Mexico City 25
Miami 25
Paris 25
Gavirate 24
Dhaka 23
Olomouc 23
Padova 23
Salt Lake City 23
Zurich 23
Totale 22.752
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 609
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 595
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 514
Genetic mechanisms of critical illness in COVID-19 455
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 446
An explainable model of host genetic interactions linked to COVID-19 severity 392
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 389
Pathogen-sugar interactions revealed by universal saturation transfer analysis 376
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 370
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 359
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 357
Mapping the human genetic architecture of COVID-19 328
Peripheral biomarkers' panel for severe COVID-19 patients 326
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 320
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 317
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 312
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 311
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 307
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 305
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 297
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 295
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 289
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 288
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 280
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 280
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 272
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 268
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 267
Prognostic bioindicators in severe COVID-19 patients 259
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 259
Serial KL-6 measurements in COVID-19 patients 256
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 254
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 252
Serum amyloid A in patients with idiopathic pulmonary fibrosis 250
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 250
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 250
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 247
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 244
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 241
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 241
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 238
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 237
NK and NKT-like cells in granulomatous and fibrotic lung diseases 235
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 234
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 233
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 232
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 231
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 230
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 230
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 230
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 229
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 226
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 222
Whole-genome sequencing reveals host factors underlying critical COVID-19 222
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 222
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 220
WES profiling of COVID-19 218
Serum amyloid A: A potential biomarker of lung disorders 213
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 212
Clinical and molecular characterization of COVID-19 hospitalized patients 211
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 208
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 208
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 207
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 205
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 204
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 203
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 203
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 201
Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases 199
Effects of rituximab therapy on B cell differentiation and depletion 199
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations 196
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 194
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 194
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 193
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 193
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study 191
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 189
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 189
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 189
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 189
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 187
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 187
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 187
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 186
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 185
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 185
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 185
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 183
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 182
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 179
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 176
Immunologic responses to antifibrotic treatment in IPF patients 173
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 170
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction 168
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 168
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review 168
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 167
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 166
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 166
Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis 166
Totale 24.940
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.324
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.324
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.863 0 0 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20256.894 603 268 757 395 788 424 381 419 535 350 627 1.347
2025/202616.198 1.057 1.926 1.751 1.859 3.101 584 2.028 485 607 1.052 598 1.150
2026/20271.886 681 538 667 0 0 0 0 0 0 0 0 0
Totale 36.313